CN100516041C - 新型杂芳基衍生物 - Google Patents

新型杂芳基衍生物 Download PDF

Info

Publication number
CN100516041C
CN100516041C CNB2004800262352A CN200480026235A CN100516041C CN 100516041 C CN100516041 C CN 100516041C CN B2004800262352 A CNB2004800262352 A CN B2004800262352A CN 200480026235 A CN200480026235 A CN 200480026235A CN 100516041 C CN100516041 C CN 100516041C
Authority
CN
China
Prior art keywords
substituted
reference example
alkyl
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800262352A
Other languages
English (en)
Chinese (zh)
Other versions
CN1849303A (zh
Inventor
渡边健一
丸田克纪
后田贯太郎
永田龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CN1849303A publication Critical patent/CN1849303A/zh
Application granted granted Critical
Publication of CN100516041C publication Critical patent/CN100516041C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
CNB2004800262352A 2003-07-15 2004-07-13 新型杂芳基衍生物 Expired - Fee Related CN100516041C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003274684 2003-07-15
JP274684/2003 2003-07-15

Publications (2)

Publication Number Publication Date
CN1849303A CN1849303A (zh) 2006-10-18
CN100516041C true CN100516041C (zh) 2009-07-22

Family

ID=34113749

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800262352A Expired - Fee Related CN100516041C (zh) 2003-07-15 2004-07-13 新型杂芳基衍生物

Country Status (11)

Country Link
US (2) US7425642B2 (enExample)
EP (1) EP1647546B1 (enExample)
JP (2) JP4820169B2 (enExample)
KR (1) KR101086654B1 (enExample)
CN (1) CN100516041C (enExample)
AT (1) ATE556051T1 (enExample)
CA (1) CA2531064C (enExample)
ES (1) ES2383895T3 (enExample)
MX (1) MXPA06000539A (enExample)
TW (1) TW200523249A (enExample)
WO (1) WO2005012245A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006075638A1 (ja) * 2005-01-14 2008-06-12 大日本住友製薬株式会社 新規ヘテロアリール誘導体
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
ATE532770T1 (de) 2006-09-05 2011-11-15 Kyowa Hakko Kirin Co Ltd Imidazolderivat
WO2008157537A2 (en) * 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
CN102202662A (zh) * 2008-10-31 2011-09-28 大日本住友制药株式会社 抗糖尿病剂
JPWO2010110440A1 (ja) 2009-03-26 2012-10-04 大日本住友製薬株式会社 新規認知機能障害治療剤
TW201105337A (en) * 2009-07-01 2011-02-16 Dainippon Sumitomo Pharma Co Medicine derived from a combination of SGLT1-inhibitor and insulin sensitizer
CA2787785C (en) 2010-01-28 2018-03-06 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2013138600A1 (en) * 2012-03-16 2013-09-19 Rosen Eliot M Radioprotector compounds
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002121186A (ja) * 2000-05-22 2002-04-23 Takeda Chem Ind Ltd チロシンホスファターゼ阻害剤
JP2003171275A (ja) * 2001-12-11 2003-06-17 Sumitomo Pharmaceut Co Ltd ＰＰＡＲδアゴニスト

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2752361A1 (de) * 1977-11-24 1979-06-07 Troponwerke Gmbh & Co Kg Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1998040385A1 (en) * 1997-03-07 1998-09-17 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
AU2001258784A1 (en) 2000-05-22 2001-12-03 Takeda Chemical Industries Ltd. Tyrosine phosphatase inhibitors
SK17342002A3 (sk) * 2000-06-26 2004-06-08 Pfizer Products Inc. Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu
WO2002085851A1 (en) * 2001-04-19 2002-10-31 Sumitomo Pharmaceuticals Company, Limited Pyrrole derivative
AU2003284479A1 (en) * 2002-11-28 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Novel heteroaryl derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002121186A (ja) * 2000-05-22 2002-04-23 Takeda Chem Ind Ltd チロシンホスファターゼ阻害剤
JP2003171275A (ja) * 2001-12-11 2003-06-17 Sumitomo Pharmaceut Co Ltd ＰＰＡＲδアゴニスト

Also Published As

Publication number Publication date
US20060194857A1 (en) 2006-08-31
JP4820169B2 (ja) 2011-11-24
EP1647546B1 (en) 2012-05-02
EP1647546A4 (en) 2008-07-23
KR20060040681A (ko) 2006-05-10
CN1849303A (zh) 2006-10-18
ES2383895T3 (es) 2012-06-27
CA2531064C (en) 2012-05-22
JP2011251974A (ja) 2011-12-15
ATE556051T1 (de) 2012-05-15
JPWO2005012245A1 (ja) 2006-09-14
MXPA06000539A (es) 2006-03-30
US20080306275A1 (en) 2008-12-11
KR101086654B1 (ko) 2011-11-24
EP1647546A1 (en) 2006-04-19
CA2531064A1 (en) 2005-02-10
TW200523249A (en) 2005-07-16
WO2005012245A1 (ja) 2005-02-10
US7425642B2 (en) 2008-09-16
HK1087409A1 (en) 2006-10-13
TWI331142B (enExample) 2010-10-01

Similar Documents

Publication Publication Date Title
CN100516041C (zh) 新型杂芳基衍生物
EP1260512B1 (en) Novel cyclic amide derivatives
EP1441719B1 (en) N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors
CN105339350B (zh) 二氢吡啶酮mgat2抑制剂
Müller Palladium-copper catalyzed alkyne activation as an entry to multicomponent syntheses of heterocycles
CN107428734A (zh) 用于雄激素受体的靶向降解的化合物和方法
CN106061968B (zh) 四唑酮-取代的二氢吡啶酮mgat2抑制剂
EP3214079B1 (en) Six-membered ring benzo derivatives as dpp-4 inhibitor and use thereof
WO2012026495A1 (ja) 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
EP3495363A1 (en) Nitrogen-containing condensed ring compound having dopamine d3 receptor antagonistic effect
WO2014010748A1 (en) Cyclopropane derivative having bace1 inhibiting activity
EP4129402A1 (en) Hydroxypyrrolidine derivative and medicinal application thereof
Chou et al. Synthesis and applications of tetrahydro-2-pyridinones via aza-Diels-Alder reactions of thio-substituted 1, 3-dienes with arylsulfonyl isocyanates
AU2002334836B2 (en) N-heterocyclyl hydrazides as neurotrophic agents
AU2002334836A1 (en) N-heterocyclyl hydrazides as neurotrophic agents
WO2004048341A1 (ja) 新規ヘテロアリール誘導体
TWI643847B (zh) Novel benzoazepine derivatives and their medical uses
JP2006036730A (ja) 新規ピロール誘導体
AU2002334837A1 (en) Triazepine derivatives as neurotrophic agents
WO2003028734A1 (en) Triazepine derivatives as neurotrophic agents
HK1087409B (en) Novel heteroaryl derivative
HK1066223B (en) N-heterocyclyl hydrazides as neurotrophic agents
JPH11217377A (ja) 新規アルキルアミノ誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090722

Termination date: 20140713

EXPY Termination of patent right or utility model